Health-economic benefits of anti-CD20 treatments in relapsing multiple sclerosis estimated using a treatment-sequence model

BACKGROUND: In high-income countries, four anti-CD20 monoclonal antibodies (mAbs) are used or in the pipeline for relapsing MS: ocrelizumab, ofatumumab (both registered), ublituximab (awaiting registration) and rituximab (off-label). List prices differ significantly between registered and off-label...

Descripción completa

Detalles Bibliográficos
Autores principales: Smets, Ide, Versteegh, Matthijs, Huygens, Simone, Corsten, Cato, Wokke, Beatrijs, Smolders, Joost
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387699/
https://www.ncbi.nlm.nih.gov/pubmed/37529628
http://dx.doi.org/10.1177/20552173231189398

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387699/
https://www.ncbi.nlm.nih.gov/pubmed/37529628
http://dx.doi.org/10.1177/20552173231189398

Ejemplares similares